|
|
| VGX
Pharmaceuticals Announces New Product Marketing and Sales Plan for
Asia and Other Developing Regions
|
| Blue
Bell, PA – October 26, 2006 – |
|
VGX Pharmaceuticals announced today the plans for eventual
marketing and sales of its developmental products for Asia as well as
other developing regions through VGX International.
The Company’s clinical development programs include PICTOVIR™
for HIV infection and VGX-410C for chronic HCV infection, which are currently
in Phase II clinical trials. In addition, several new Phase I clinical
trials are prepared to be initiated in 2007 with a strong pipeline, which
includes VGX-150 for Melanoma and VGX-100 for Lymphoma/Leukemia and Gastric
Cancer as well as VGX-1027 for the treatment of Rheumatoid Arthritis and
Type 1 Diabetes.
“We at VGX have always kept our corporate focus on improving the
lives of patients through new medicines and effectively delivering our
products to the people who most need them,” said J. Joseph Kim,
Ph.D., President and CEO of VGX Pharmaceuticals. “As we develop
our compounds through rigorous clinical testing, we are also planning
the most efficient and productive avenues to bring our products to our
consumers worldwide. This represents an initial step in the formation
of a coordinated business plan in transforming VGX Pharmaceuticals and
VGX International into global pharmaceutical companies,” said Dr.
Kim.
Cautionary
Factors That May Affect Future Results - Materials in this
Web site contain information that includes or is based upon forward-looking
statements within the meaning of the Securities Litigation Reform
Act of 1995. Forward-looking statements relate to expectations or
forecasts of future events. You can identify these statements by the
fact that they do not relate strictly to historical or current facts.
They use words such as "anticipate," "estimate,"
"expect," "project," "intend," "plan,"
"believe," and other words and terms of similar meaning
in connection with a discussion of potential future events, circumstances
or future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of contingencies
such as legal proceedings, and financial results. Any or all of our
forward-looking statements here or in other publications may turn
out to be wrong. They can be affected by inaccurate assumptions or
by known or unknown risks and uncertainties. Many such factors will
be important in determining our actual future results. Consequently,
no forward-looking statement can be guaranteed, and forward-looking
statements may be adversely affected by factors, including general
market conditions, competitive product development, product availability,
current and future branded and generic competition, federal and state
regulations and legislation, manufacturing issues, timing of the elimination
of trade buying, patent positions, litigations and investigations.
Our actual results may vary materially, and there are no guarantees
about the performance or valuation of VGX stock. It is also important
to read the disclosure notice contained in many of the individual
VGX documents available on this Web site as many contain important
information on such cautionary factors as of the date of the individual
document. We undertake no obligation to correct or update any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are advised, however, to consult any further disclosures
we make on related subjects in our reports. |
About
VGX Pharmaceuticals
VGX Pharmaceuticals is a leading biopharmaceutical company with strong product
candidates for the treatment of infectious diseases including HIV and hepatitis
C virus (HCV) as well as cancer and inflammatory diseases. The Company’s
clinical development programs include PICTOVIR™ for HIV infection
and VGX-410C for chronic HCV infection, which are currently in Phase II
clinical trials. In addition, a Phase I clinical trial will be initiated
in 2007 for the Company’s lead cancer drug compound, VGX-150 for the
treatment of Melanoma. Moreover, VGX Pharmaceuticals’ therapeutic
platform is designed to advance a strong and continual pipeline of additional
drug candidates into the clinic with VGX-100 for cancer therapy and VGX-1027
and VGX-750 for inflammatory diseases currently in development. The product
candidates and technology programs are protected by the Company’s
extensive global intellectual property portfolio. More information about
VGX can be found at www.vgxp.com.
About VGX International
VGX International is a KOSPI-listed company, located in Seoul, Korea with
more than 30 years in manufacturing and marketing industries. In 2005, the
Company initiated a Biopharmaceutical division with collaborations with
VGX Pharmaceuticals. In addition to a plan to initiate building an API manufacturing
facility with the API agreement signed with VGX Pharmaceuticals in 2006,
the Company is in the process of launching new drug developments for stomach
cancer and type 1 diabetes among others. Furthermore, VGX International
will formulate marketing strategies for such new drugs in Asia and other
developing regions. More information about VGX International can be found
at www.vgxi.com.
Company Contact:
Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com
|
